Delving into the Latest Updates on Huaier Granule with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Frailty Syndrome

Inactive Indication

Stage III Colon Cancer

Originator Organization

Qidong Gaitianli Medicines Co., Ltd.

Active Organization

Qidong Gaitianli Medicines Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (24 Jun 2020),

Frailty Syndrome

Regulation-

Login to view timeline

BACKGROUNDTriple-negative breast cancer (TNBC) is the most intractable subgroup of breast neoplasms due to its aggressive nature. In recent years, immune checkpoint inhibitors (ICIs) have exhibited potential efficacy in TNBC treatment. However, only a limited fraction of patients benefit from ICI therapy, primarily because of the suppressive tumor immune microenvironment (TIME). Trametes robiniophila Murr (Huaier) is a traditional Chinese medicine (TCM) with potential immunoregulatory functions. However, the underlying mechanism remains unclear.PURPOSEThe present study aimed to investigate the therapeutic role of Huaier in the TIME of TNBC patients.METHODSSingle-cell RNA sequencing (scRNA-seq) was used to systematically analyze the influence of Huaier on the TNBC microenvironment for the first time. The mechanisms of the Huaier-induced suppression of cancer-associated fibroblasts (CAFs) were assessed via real-time quantitative polymerase chain reaction (qRT‒PCR) and western blotting. A tumor-bearing mouse model was established to verify the effects of the oral administration of Huaier on immune infiltration.RESULTSUnsupervised clustering of the transcriptional profiles suggested an increase in the number of apoptotic cancer cells in the Huaier group. Treatment with Huaier induced immunological alterations from a "cold" to a "hot" state, which was accompanied by phenotypic changes in CAFs. Mechanistic analysis revealed that Huaier considerably attenuated the formation of myofibroblastic CAFs (myoCAFs) by impairing transforming growth factor-beta (TGF-β)/SMAD signaling. In mouse xenograft models, Huaier dramatically modulated CAF differentiation, thus synergizing with the programmed cell death 1 (PD1) blockade to impede tumor progression.CONCLUSIONSOur findings demonstrate that Huaier regulates cancer immunity in TNBC by suppressing the transition of CAFs to myoCAFs and emphasize the crucial role of Huaier as an effective adjuvant agent in immunotherapy.

01 Dec 2024·Molecular Biology Reports

Huaier inhibits cholangiocarcinoma cells through the twist1/FBP1/Wnt/β-catenin axis

Article

Author: Zhao, Jing ; Cong, Liyuan ; Li, Kun ; Zhang, Bingyuan ; Dai, Dongdong ; Zhao, Wei ; Shi, Jian

BACKGROUNDAlthough Huaier granules can be used as prospective anti-cholangiocarcinoma drugs, the mechanism of action of Huaier granules in cholangiocarcinoma is not clear. The anti-cholangiocarcinoma effect of Huaier granules was validated in cell line research. In vitro experiments were conducted to investigate the signalling pathways affected by Huaier in CCA cells.METHODS AND RESULTSReal-time quantitative PCR (RT‒qPCR) and Western blot analysis were performed to analyse gene expression in CCA cells. MTT assays, scratch tests, and Transwell assays were used to explore the effects on the proliferation and metastasis of CCA cells. Chromatin immunoprecipitation assays were performed to reveal the potential underlying mechanisms involved. Twist1 was upregulated in human CCA tissues. In addition, its expression levels were negatively related to FBP1 expression levels. Mechanistically, Twist1 can bind to the region of the FBP1 promoter to reduce its expression. Huaier plays an indispensable role in suppressing Twist1 expression to inhibit the Twist1/FBP1/Wnt/β-catenin axis. Then, we verified the effect of Huaier in vitro.CONCLUSIONSThese findings suggested that Huaier granules were capable of inhibiting CCA development through regulating the Twist1/FBP1/Wnt/β-catenin signalling axis and provided a novel orientation for the development of novel anti-CCA drugs.

01 Feb 2024·Translational Cancer Research

Huaier granule improves liver inflammation and fibrosis and prevents recurrence in hepatitis B virus related hepatocellular carcinoma

Article

Author: Zeng, Jianxing ; Wu, Qionglan ; Huang, Yao ; Zeng, Jinhua

BackgroundThere is basic research suggesting that Huaier granule can inhibit liver cirrhosis and hepatocellular carcinoma (HCC), but this conclusion has not been clinically verified. We analyzed the distant cancer tissue of two groups of hepatitis B virus (HBV) related HCC with/without Huaier granule, to clarify the effect of Huaier granule on liver inflammation, liver fibrosis, and postoperative recurrence.MethodsWe collected clinicopathological data of HCC patients who received two surgery procedures at Mengchao Hepatobiliary Hospital of Fujian Medical University in China from January 2014 to December 2020. Patients according to taking/not taking Huaier granule after the first hepatectomy were divided into two groups, 51 patients with Huaier granule for more than 6 months after operation (Group A); 56 patients without Huaier granule (Group B). The effects on liver inflammation, fibrosis grade, and postoperative recurrence were compared between two groups.ResultsThe results showed that liver inflammation improved significantly in the Group A [19 (37.3%) cases improved, 31 (60.8%) cases remained unchanged, and 1 (2.0%) case deteriorated] was significantly more than that in the Group B [7 (12.5%) cases improved, 32 (57.1%) cases remained unchanged, and 17 (30.4%) cases deteriorated] (P<0.001). The liver fibrosis in the Group A [17 (33.3%) cases improved, 32 (62.7%) cases remained unchanged, and 2 (3.9%) cases deteriorated] was significantly improved in the Group B [5 (8.9%) cases improved, 45 (80.4%) cases remained unchanged, and 6 (10.7%) cases deteriorated] (P=0.005). The recurrence interval (27.0±21.2 months) in the Group A was significantly longer than that in the Group B (19.0±14.2 months) (P=0.026).ConclusionsHuaier granule can improve liver inflammation, fibrosis, and liver function and prolong the time to recurrence in HBV-related HCC. Given the high rate of postoperative recurrence and poor prognosis of HBV-related HCC, our findings may have useful clinical significance in the prevention of tumor recurrence in these patients.

100 Deals associated with Huaier Granule

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Frailty Syndrome	China	Qidong Gaitianli Medicines Co., Ltd.	24 Jun 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stage III Colon Cancer	Preclinical	China	Qidong Gaitianli Medicines Co., Ltd.	01 Jun 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2023	Not Applicable	Hepatocellular Carcinoma	-	Huaier granule group	(ihpmyvedxe) = chilvcvphj mhhejcyqeq (aaddtwonki )	Positive	31 May 2023
				Huaier granules (Control group)	(ihpmyvedxe) = rlxeamncbi mhhejcyqeq (aaddtwonki )
CSCO2020	Not Applicable	Hepatocellular Carcinoma Adjuvant	340	Huaier granules (Single thermal ablation)	wkyqvmhifj(pibsuleimn) = The combined treatment group presented more obvious nausea and emesis side effects, but the differences were not statistically significant fhgarztubu (ctqdvaywbh )	-	19 Sep 2020
EASL2019	Phase 4	Hepatocellular Carcinoma Adjuvant	-	Huaier granule	(wnmvpdkmaj) = vxeuueijrq vylocdxmee (ksqvpbumel ) View more	Positive	12 Apr 2019
				huaier granule (No further treatment (controls))	(wnmvpdkmaj) = ezwbpudpgq vylocdxmee (ksqvpbumel ) View more
NCT01770431 (Pubmed \| Gut)	Phase 4	Hepatocellular Carcinoma Adjuvant	1,044	Huaier granule	(uxsyqrbmgl) = ubqfmfrxgu xteagzvzzy (wosgmfciha ) View more	Positive	01 Nov 2018
				Huaier granule (No further treatment)	(uxsyqrbmgl) = dtfgdnuvdj xteagzvzzy (wosgmfciha ) View more
WCLC2018	Not Applicable	Adenocarcinoma of Lung	40	Huaier Aqueous Extract	kabqipkdgg(kkufojacfm) = vqktwyyeyf ogaozcmhwb (jwtpcrhmut )	-	24 Sep 2018
NCT01770431 (CTgov)	Phase 4	Hepatocellular Carcinoma	1,044	Huaier Granule (Huaier Granule Group)	xcqihrlqhg(hvcgimnrbl): chi-squared = 14.7315, P-Value = 0.0001 View more	-	02 Oct 2017
				Huaier Granule (Bank-control Group)